Bristol Myers Squibb Reports meta-analysis Data for Filgotinib in Chronic hand eczema

Bristol Myers Squibb today announced meta-analysis results for Filgotinib in patients with Chronic hand eczema. The study demonstrated that Filgotinib demonstrates superior efficacy vs standard of care compared to standard of care or placebo. These results provide important insights into the treatment of Chronic hand eczema and support the continued development of Filgotinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Filgotinib was consistent with previous observations, with no new safety signals identified.